Fig. 2

CCNB2 is overexpressed in gastric cancer tissues and serves as a prognostic indicator of poor outcomes. (A) Representative images illustrating CCNB2 expression in cancerous versus normal tissue, assessed via immunohistochemistry (IHC). (B) Kaplan-Meier survival analysis depicting the survival rates of patients diagnosed with gastric cancer. (C) Western blot analysis quantifying CCNB2 protein levels in twelve gastric cancer specimens alongside adjacent non-cancerous gastric tissues. Overall survival of all patients was significantly associated with CCNB2 expression (p = 0.0014).